sunitinib fmk 37,5mg tvrdá tobolka
farmak international sp.z.o.o., varšava array - 17420 sunitinib - tvrdá tobolka - 37,5mg - sunitinib
sunitinib fmk 50mg tvrdá tobolka
farmak international sp.z.o.o., varšava array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib
sunitinib zentiva 12,5mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 12,5mg - sunitinib
sunitinib zentiva 25mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 25mg - sunitinib
sunitinib zentiva 37,5mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 37,5mg - sunitinib
sunitinib zentiva 50mg tvrdá tobolka
zentiva, k.s., praha array - 17420 sunitinib - tvrdá tobolka - 50mg - sunitinib
cyclo 3 fort 150mg/150mg/100mg tvrdá tobolka
pierre fabre medicament, lavaur array - 13453 suchÝ listnatcovÝ extrakt; 709 hesperidin-methylchalkon; 102 kyselina askorbovÁ - tvrdá tobolka - 150mg/150mg/100mg - rutosid, kombinace
sumamed 250mg tvrdá tobolka
teva pharmaceuticals cr, s.r.o., praha array - 10264 dihydrÁt azithromycinu - tvrdá tobolka - 250mg - azithromycin
thromboreductin 0,5mg tvrdá tobolka
aop orphan pharmaceuticals gmbh, wien array - 20621 monohydrÁt anagrelid-hydrochloridu - tvrdá tobolka - 0,5mg - anagrelid
xtandi
astellas pharma europe b.v. - enzalutamid - prostatetické novotvary - endokrinní terapie - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.